DarioHealth Corp (NASDAQ: DRIO), a global digital therapeutics innovator, is collaborating with the American Diabetes Association (ADA) as a Living Red Sponsor of NYC - Step Out: Walk to Stop Diabetes, it was reported on Friday.
Dario will publish several studies performed using de-identified data from its broad data base of users, showcasing the clinical benefits of its Digital Therapeutics solution to help improve life with diabetes and achieve clinically-proven results at the ADA's 2019 Scientific Sessions conference in June 2019. The company offers a user mobile application to engage and educate its users on topics ranging from diabetes management to healthy nutrition and exercise, as well as a platform that allows healthcare professionals to access collected data and to provide recommendations to the individuals they are supporting. Data is collected from devices such as the Dario 3-in-1 blood glucose meter and other applications. Dario is an open system accepting connections with third party devices and external health coaches. It delivers aggregated analytics demonstrating the efficacy of its interventions.
Erez Raphael, DarioHealth's CEO, said, 'We are honoured and humbled to be recognised by the ADA as an organisation that can advance the ADA's cause of preventing and curing diabetes. Dario is striving to use its technology and expertise to engage its users in adopting healthier habits, with scientific-based results.'
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes